TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers report that over-expressing the gene SRSF1 reduced several aging-related features in human skin fibroblast cells while preserving their identity. In aged mice, the intervention was associated with a 14% lifespan extension, but the findings do not establish safety or effectiveness in people.
A team led by researchers at Harvard’s Wyss Institute reports that the gene SRSF1 reduced several aging-related features in human skin cells and extended lifespan by 14% in aged mice. The findings, published in Nature Aging, point to a possible route for rejuvenating cells while retaining their specialized identity, but they do not show that the approach is safe or effective in humans.
The researchers first built a machine-learning age predictor using gene-expression profiles from human skin fibroblasts. Fibroblasts are connective-tissue cells, and the model was designed to estimate their “transcriptomic age” from patterns of gene activity. The team tested it on cells from donors aged 55, 65 and 79, and used it to assess whether experimental interventions shifted cells toward a younger expression profile.
They then screened a focused set of genes thought likely to affect aging. According to the study, over-expressing SRSF1, which encodes an RNA-processing factor, lowered the cells’ transcriptomic age score and reduced features associated with cellular senescence, proteostatic stress and inflammation. The report describes those changes as aging-related; a younger score on a molecular model is not itself proof that a cell or organism has been restored to a younger functional state.
The team also delivered SRSF1 to aged mice. The gene primarily accumulated in the liver, and the researchers reported a reduced rate of aging and a 14% increase in lifespan. The source report does not provide details here on the number of animals, the precise delivery method, or the full experimental conditions. The mouse result is not evidence of a comparable lifespan effect in people.
A Route Beyond Yamanaka Factors
The work addresses a central challenge in experimental cellular rejuvenation: shifting aging-related processes without erasing the functions that make a cell a skin cell, liver cell or another specialized type. Earlier research showed that brief exposure to the Yamanaka factors can move some mature cells toward a younger state, but stronger or prolonged reprogramming can push cells toward an undifferentiated state and raise concerns about loss of cell identity and cancer risk.
SRSF1 is presented as a possible alternative target, not as a proven safer therapy. If further studies confirm that it can improve tissue function without harmful effects, gene-based interventions could potentially be tailored to particular tissues. For now, the evidence described is a combination of cellular measurements and a mouse experiment, so its relevance to human healthspan remains unknown.
The distinction matters because the study’s age predictor measures gene-expression patterns, while the broader aim is to preserve or improve how tissues work. A lower transcriptomic age score may help researchers compare interventions and select candidates, but it does not establish that an organism has become biologically younger across all organs or that age-related disease has been prevented.
As an affiliate, we earn on qualifying purchases.
How the Study Tested Cell Age
Researchers have long sought ways to intervene in biological processes associated with aging, including senescence, disrupted protein maintenance and chronic low-grade inflammation. The source report describes these as among the hallmarks of aging—processes scientists investigate as possible targets for preserving tissue function.
Yamanaka’s discovery that four genes can reprogram mature cells into a pluripotent state helped establish that cellular identity can be altered. Short, controlled exposure has also been studied as a means of partial reprogramming. But concerns about inappropriate reprogramming and cancer risk have prompted searches for other targets. The present study, led by George Church and spearheaded by first co-author Alex Plesa, worked with Antonio del Sol’s computational biology group at CIC bioGUNE-BRTA in Spain.
The team’s transcriptomic predictor was intended as a screening tool. Plesa said it made sense to estimate age through gene expression because rejuvenation processes would be expected to alter gene-activity programs. The researchers used the model to rank candidate genes, then tested the leading candidate in cells and aged mice. This approach differs from commonly used epigenetic clocks, which assess age-related chemical changes to DNA, and which Plesa said can be costly and difficult to scale for screening.
“In reprogramming, there is a fundamental tradeoff between rejuvenation and cell identity; achieving one without losing the other requires walking a fine line.”
— Alex Plesa, Ph.D., study first co-author
As an affiliate, we earn on qualifying purchases.
Human Safety and Benefit Remain Unknown
The findings do not establish that SRSF1 treatment can rejuvenate people, extend human lifespan or prevent age-related illness. The reported evidence includes changes in cultured human fibroblasts and an outcome in aged mice; it does not include a human trial. It is also unclear from the source report how long the effects lasted, whether benefits appeared in tissues beyond the liver, or what adverse effects occurred during the animal study.
The 14% lifespan figure is reported for the mouse experiment, but the source material provided does not specify the study’s animal count, comparison group details or statistical uncertainty. Those details are needed to judge the strength and limits of the result. Nor does the report establish that the intervention avoids cancer risk or other harms associated with gene manipulation. The claim that SRSF1 may offer a way to preserve cell identity remains a research direction, not a demonstrated clinical outcome.
As an affiliate, we earn on qualifying purchases.
Further Testing Before Clinical Use
The researchers’ stated aim is to identify genes that could eventually be engineered for under- or over-expression in aging target tissues. The next research steps would need to test whether SRSF1’s effects can be reproduced, clarify how it changes aging-related biology, and examine safety and function across additional tissues and longer periods.
Any future gene therapy would also require a delivery method that reaches the intended tissue and controls the level and duration of gene expression. The study’s authors describe tissue-specific gene therapy as a potential direction, but the source report does not announce a clinical trial or a timeline for one. Until further evidence is available, the findings should be understood as a preclinical research result rather than a treatment option.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find?
The researchers reported that over-expressing SRSF1 reduced several aging-associated features in human skin fibroblasts. In aged mice, they reported a 14% lifespan extension after delivering the gene.
Was the gene therapy tested in people?
No human trial is described in the source report. The evidence presented covers cultured human cells and an experiment in aged mice, so human safety and effectiveness are unknown.
What does “preserving cell identity” mean here?
It refers to the goal of making aging-related changes without turning a mature, specialized cell into an undifferentiated cell. The study presents SRSF1 as a potential way to address that challenge; it does not establish clinical proof that identity is preserved in every tissue or setting.
Does a lower transcriptomic age score prove a cell is younger?
No. The score reflects gene-expression patterns used by the researchers’ model. It can help compare experimental interventions, but a lower score alone does not prove improved tissue function, longer life or reduced disease risk.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
